Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
460 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT07085767
#2025-522873-12-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Olema Pharmaceuticals, Inc.
Phase 3
Lung cancer
#NCT06868277
#2024-517780-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
12 recruiting sites
AstraZeneca
Phase 3
Colon cancer
Rectal cancer
#NCT06662786
#2024-513852-13-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
HER2
KRAS G12C
KRAS non G12C
MSI/dMMR
NRAS
7 recruiting sites
Janssen
Phase 3
Lung cancer
#NCT06472245
#2023-509340-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
29 recruiting sites
OSE Immunotherapeutics
Phase 3
Breast cancer
#NCT05894239
#2022-502046-28-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
5 recruiting sites
Hoffmann-La Roche
Phase 3
Head and neck cancer
#NCT06064877
Required histologic types
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Salivary glands
Nasal cavities and sinuses
Other
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
AVEO Pharmaceuticals, Inc.
Phase 3
Stomach and esophageal cancer
#NCT06764875
#2024-512583-57-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
7 recruiting sites
AstraZeneca
Phase 3
Stomach and esophageal cancer
#NCT06346197
#2023-506291-28-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Centre Léon Bérard
Phase 3
Prostate cancer
#NCT06626022
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Targeted therapy
Radiotherapy
Hormone therapy
Internal Vectorised Radiotherapy (IVR)
1 recruiting site
University of Alberta
Phase 3
Thymus cancer
#NCT05918302
#2022-502154-13-00
Required histologic types
Other
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
2
8 recruiting sites